Temporal development of 2',3'-dideoxyinosine (ddI)-induced peripheral myelinopathy.
The anti-HIV therapeutic dideoxyinosine (ddI) has been reported to produce a painful, dose-limiting peripheral myelinopathy in HIV-infected patients after chronic administration. We have previously demonstrated ddI-induced myelinopathy in a non-HIV-infected rat model after 20 weeks of dosing, characterized by myelin splitting and intramyelin edema. The present study examined the time course needed to produce the ddI-induced neuropathy. Adult male Sprague-Dawley rats were gavaged with vehicle or 415 mg/kg ddI twice daily for up to 20 weeks. Groups of treated (n = 6-8) and control (n = 3-5) animals were killed after 5, 10, 15, and 20 weeks of dosing and the distal end of the sciatic nerve was removed. The nerve was postfixed by immersion in neutral phosphate-buffered formalin, dehydrated in graded alcohols, and embedded in plastic embedding media. One-micrometer-thick sections were cut and stained with toluidine blue and basic fuchsin. Plasma levels of ddI on the day the animals were killed were greater than 10 microgram/ml within the first hour after dosing and fell rapidly to less than 1 microgram/ml (clinical range 1-2 microgram/ml) within 3 h after dosing. The abnormalities observed in the sciatic nerve were few, if any, after 5 or 10 weeks, but very prominent after 15 weeks of dosing. Four of the six ddI-treated rats exhibited abnormal morphology as evidenced by myelin splitting and ballooned myelin sheaths. Although abnormal morphology was present at 20 weeks of dosing, the effect was not as robust as at 15 weeks. This suggests that the nerve may partially recover from the effects of ddI with time. Published by Elsevier Science Inc.
Patterson
T A
TA
Division of Neurotoxicology, National Center for Toxicological Research/FDA, 72079-9502, Jefferson, AR, USA. tpatterson@nctr.fda.gov
Schmued
L C
LC
Sandberg
J A
JA
Slikker
W
W
D000818:Animals; D019380:Anti-HIV Agents / Q000097:blood / Q000633:toxicity*; D001774:Blood Chemical Analysis; D016049:Didanosine / Q000097:blood / Q000633:toxicity*; D008297:Male; D009186:Myelin Sheath / Q000473:pathology*; D020258:Neurotoxicity Syndromes / Q000473:pathology*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012584:Sciatic Nerve / Q000473:pathology
D019380:Anti-HIV Agents; D016049:Didanosine